{"id":2547,"date":"2025-01-23T14:50:06","date_gmt":"2025-01-23T11:50:06","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=2547"},"modified":"2025-11-03T20:31:05","modified_gmt":"2025-11-03T17:31:05","slug":"fda-grants-rare-pediatric-disease-designation-to-nippon-shinyakus-exon-51-skipping-study-ns-051-ncnp-04","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/pt\/fda-grants-rare-pediatric-disease-designation-to-nippon-shinyakus-exon-51-skipping-study-ns-051-ncnp-04\/","title":{"rendered":"FDA concede designa\u00e7\u00e3o de doen\u00e7a pedi\u00e1trica rara ao estudo de salto do exon 51 da Nippon Shinyaku (NS-051\/NCNP-04)"},"content":{"rendered":"<p class=\"wp-block-paragraph\">A Nippon Shinyaku e o National Center of Neurology and Psychiatry descobriram em conjunto o oligonucleot\u00eddeo antisense NS-051\/NCNP-04. Ao omitir uma parte do material gen\u00e9tico do gene da distrofina, o NS-051\/NCNP-04 cria uma prote\u00edna distrofina funcional com um comprimento de cadeia um pouco menor, o que deve prevenir o decl\u00ednio da fun\u00e7\u00e3o muscular.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Com um forte senso de prop\u00f3sito, a Nippon Shinyaku vem desenvolvendo ativamente medicamentos para curar doen\u00e7as incomuns e intrat\u00e1veis, a fim de introduzir rapidamente solu\u00e7\u00f5es para pacientes com DMD.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Ler mais<\/strong>:\u00a0<a href=\"https:\/\/dmdwarrior.com\/pt\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Ensaios cl\u00ednicos para distrofia muscular de Duchenne (lista de todas as pesquisas)<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Nippon Shinyaku and the National Center of Neurology and Psychiatry jointly discovered the antisense oligonucleotide NS-051\/NCNP-04. By omitting a portion of the dystrophin gene&#8217;s genetic material, NS-051\/NCNP-04 creates a functioning dystrophin protein with a little shorter chain length, which should prevent the decline in muscle function. With a strong sense of purpose, Nippon Shinyaku has [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2550,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[193,194,88,136,192],"class_list":["post-2547","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-exon-51-skipping","tag-exon-51-treatment","tag-fda","tag-nippon-shinyaku","tag-ns-051-ncnp-04"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts\/2547","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/comments?post=2547"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts\/2547\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/media\/2550"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/media?parent=2547"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/categories?post=2547"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/tags?post=2547"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}